Induction Chemotherapy Combined With Camrelizumab in Locoregionally

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05848011` - A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer	Phase 2
Recruiting	`NCT05161572` - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer	Phase 2
Recruiting	`NCT06165900` - Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC	Phase 2
Recruiting	`NCT06120127` - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence	Phase 2
Recruiting	`NCT06262581` - Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery	Phase 2
Recruiting	`NCT05176002` - Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.	Phase 1/Phase 2
Not yet recruiting	`NCT05909137` - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Recruiting	`NCT04500990` - MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational Study
Not yet recruiting	`NCT04372732` - Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC
Completed	`NCT02692976` - Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients	Phase 2
Completed	`NCT03763630` - MAPS & ITEC Cohorts: 6-8 Years Follow-up	Phase 2
Not yet recruiting	`NCT06012318` - Dynamic Follow-up of Symptoms Based on Patient-reported Outcomes in Immunotherapy for Esophageal Cancer: a Prospective Multicentre Cohort Study (SPRING)
Not yet recruiting	`NCT05479240` - Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer	Phase 2
Recruiting	`NCT04711330` - Response and Toxicity Prediction by Microbiome Analysis After Concurrent Chemoradiotherapy
Recruiting	`NCT05515796` - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors	Phase 2
Recruiting	`NCT03683407` - Effect of Chemotherapy on TMB in NSCLC
Recruiting	`NCT03701607` - Effect of Chemotherapy on PD-L1 in NSCLC
Completed	`NCT03357861` - Cancer Patients Treated With Immunotherapy in Intensive Care Unit
Recruiting	`NCT05223088` - Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer	Phase 2
Completed	`NCT05657262` - Effect of Z Technıque on Pain, Comfort, Symptoms in Ummunotherapy Areas	N/A

NCT number	NCT04539600
Study type	Interventional
Source	Sun Yat-sen University
Contact	Shuang Wu, doctor
Phone	+862087755766
Email	wush77@mail.sysu.edu.cn
Status	Recruiting
Phase	Phase 2
Start date	November 1, 2020
Completion date	December 12, 2022

Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms